|Bid||14.09 x 1400|
|Ask||14.10 x 4000|
|Day's range||13.99 - 14.10|
|52-week range||13.91 - 19.97|
|Beta (5Y monthly)||1.10|
|PE ratio (TTM)||11.72|
|Forward dividend & yield||0.84 (5.92%)|
|Ex-dividend date||30 Mar 2021|
|1y target est||20.37|
Seagen (SGEN) focuses on improving sales of its marketed drugs that are approved for different types of cancer indications. Stiff competition in the target market remains a woe.
WORCESTER, Mass., October 13, 2021--BioLife Plasma Services announces new center opening in Worcester, MA to support an urgent need for plasma donations.
OSAKA, Japan & CAMBRIDGE, Mass., October 07, 2021--Takeda Pharmaceutical Company Limited (TSE:4502/NYSE:TAK) ("Takeda") today announced the U.S. Food and Drug Administration (FDA) Antimicrobial Drugs Advisory Committee (AMDAC) voted unanimously to recommend use of maribavir (TAK-620) for the treatment of refractory cytomegalovirus (CMV) infection and disease with genotypic resistance to ganciclovir, valganciclovir, foscarnet or cidofovir in transplant recipients. The committee also voted unanimo